Pfizer COVID-19 jab declines faster than AstraZeneca: study
The effectiveness of the Pfizer-BioNTech vaccine against COVID-19 declines faster than that of the AstraZeneca jab, according to a new study published on August 19. "Two doses of Pfizer-BioNTech have greater initial effectiveness against new COVID-19 infections, but this declines faster compared with two doses of Oxford-AstraZeneca," researchers at Oxford University said. It found that "the dynamics of immunity following second doses differed significantly" between Pfizer and AstraZeneca, according to the university's Nuffield Department of Medicine. Pfizer had "greater initial effectiveness" but saw "faster declines in protection against high viral burden and symptomatic infection", when looking at a period of several months after full vaccination, although rates remained low for both jabs.
AstraZeneca begins global withdrawal of Covid-19 vaccines: This is the reason
AstraZeneca Covid Jab Linked to 30% Higher Risk of Very Rare Blood Clot: Study
Pfizer to offer low-cost vaccines and medicines in some of world's poorest nations
AstraZeneca Covid Booster Shot Effective Against Severe Disease, UK Study Finds
Fourth jab’s protection against Covid is short lived for those above 60: Study
Pfizer Covid vaccine less effective in South Africa after Omicron cases: Study
Discover Related
Health Council: no COVID-19 vaccine needed for adults under 50 who get flu shot
Hiltzik: Should this paper on COVID vaccines have been published?
Breakthrough in next-generation polio vaccine. It is safer and cheaper
What is the cancer vaccine Russia is offering? | Explained
Why Americans are opting out of getting a COVID booster shot
Revealed: The common medications that make your flu shot less effective
FDA approves updated COVID-19 vaccines; shots should be available in days
COVID-19 variant KP.3.1.1 predominant in US as infections continue ticking up
Serum Institute of India's new 'high efficacy' malaria vaccine rolls out in Africa
Here are the numbers: COVID-19 is ticking up in some places, but levels remain low
US health officials strengthen endorsement of RSV shots for oldest Americans
Column: How a blunder by a respected medical journal is fueling an anti-vaccine lie
FDA advisers urge targeting JN.1 strain in recipe for fall’s COVID vaccines
Over 30% of Covaxin takers faced nervous system disorders, menstrual abnormalities: Study
1 in 3 Covaxin takers reported adverse events, BHU study claims
AstraZeneca's Covid vaccine linked to another rare blood disorder
UN agency authorizes second vaccine against dengue amid outbreaks in the Americas